was used for all soft tissue sarcomas. In the 8th edition, which is specific to tumors of the trunk and extremity, the tumor (T) category is divided into four subcategories based on tumor size, with new classifications for tumors [ 10 cm but B 15 cm (T3), and tumors [ 15 cm (T4) . Previously patients with tumors [ 10 cm were grouped into a single category (T2) without further distinction (Fig. 1) . The newly designed T-stage results in the creation of two new stage categories (IIIA and IIIB), with the former 7th edition stage IIB patients absorbed into these categories. In addition, the 8th edition staging system upstages any patient with metastatic nodal disease to stage IV (Fig. 1) . These changes were largely based on retrospective examination of data from two large, single-institution studies. 5, 6 With 5267 patients treated over an 18-year time period, Maki et al. 5 demonstrated that local recurrence-free survival (LRFS), recurrence-free survival (RFS), and diseasespecific survival (DSS) continued to diminish as tumor size increased. Regarding lymph node status, patients with N1 metastatic disease (regardless of tumor grade) in the absence of distant metastases had survival outcomes inferior to patients with large, high-grade tumors without nodal metastases (7th edition stage III), but superior to patients with distant metastatic disease (stage IV), resulting in outcomes intermediate to what are defined as stages III and IV in the AJCC 7th edition, a finding that has been reported by other groups. 7 These data were used to support the designation of N1 metastatic disease as stage IV in the 8th edition. Finally, after controlling for other significant prognostic factors such as age, size, site, and grade, tumor depth was not an independent prognostic factor for DSS, supporting the decision in the 8th edition to remove the superficial/deep classification entirely. 5, 6 These large retrospective studies 5, 6 summarize extensive experience with trunk and extremity soft tissue sarcoma, but reflect the practice patterns of highly specialized centers over long time periods. The NCDB offers a more generalized cross-sectional assessment of practice patterns across the country, while maintaining high cancerspecific standards of care. The current study uses the NCDB to assess the discriminatory ability of the new AJCC 8th edition staging system. IB  II  IIIA  IIIB  IV  Total   IIA   III  IV  Total   IIB   IA  IA  IB  IB  IIA  II   IIIA   IIIB   IV   III   IV   IIB   T1 N0 M0 G1  T1 N0 M0 G1   T2/3/4 N0 M0 G1  T1 N0 M0 G2/3  T2 N0 M0 G2/3   T3/4 N0 M0 G2/3   T2 N0 M0 G1  T1 N0 M0 G2/3   T2 N0 M0 G2   T2 N0/1 M0 G3   T any N0/1 M1 G any  T any N0/1 M1 G any   No change   No change   Renamed   Contributes to IIIA   T size splits  into IIIA or IIIB   N1 becomes IV   TX   T0   T1   T2   T3   T4 Primary cannot be assessed 441  975  4,145   754  3,526  211  2,565  2,776   2,976  4,551  6,441  1,729  7,882  2,565  26,144  5,120  4, Oncology, Third Edition, topography codes C471, C472, C476, C491, C492, and C496. 8 All histologic subtypes included in the data were individually vetted to exclude non-sarcomatous or mixed histologies. Patients with sarcomas of the retroperitoneum, head and neck or central nervous system, osteosarcomas, or dermatofibrosarcoma protuberans were excluded, as were pediatric patients, patients with significant gaps in their clinical data, patients with \ 90 days of follow-up, and/or patients with inadequate information for tumor, node, and metastasis (TNM) staging for classification according to the AJCC 7th or 8th edition staging. Due to diagnostic ambiguity, patients who were recorded as having metastatic nodal disease, yet had no pathologic assessment of lymph nodes, were also excluded, along with patients with localized disease who did not undergo surgical resection (inclusions and exclusions are summarized in electronic supplementary Fig. 1 ).
METHODS

After obtaining Institutional
Overall survival (OS) was compared using KaplanMeier curves, and Cox proportional hazard models were used to estimate 5-year OS. Univariate and multivariate analyses were performed to identify factors associated with OS. Concordance indices (C-index) were calculated to evaluate the discriminatory power of both the 7th and 8th AJCC staging editions. Statistical significance was defined at p \ 0.05. All analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Patient Characteristics
Demographics and clinical characteristics of the 26,144 patients with trunk or extremity sarcomas are shown in Table 1 . The most common histologies were liposarcoma (n = 5437 20.8%), malignant fibrous histiocytoma (n = 3675, 14.1%), leiomyosarcoma (n = 3570, 13.7%), fibrosarcoma (n = 2734, 10.5%), giant cell sarcoma (n = 2300, 8.8%), sarcoma not otherwise specified (n = 1917, 7.3%), and synovial sarcoma (n = 1326, 5.1%). Between 2004 and 2013, the number of cases per year appeared similar, with 8.1-11.0% of the total number of cases occurring each year. Most patients were treated with surgical resection [either radical resection (n = 13,499, 51.6%) or partial resection (n = 9838, 37.6%)], with amputation in a minority of patients (n = 1373, 5.3%). Radiation therapy was administered to 13,249 (50.7%) patients, and chemotherapy was administered to 4525 (17.3%) patients.
Staging
With the addition of the T3 and T4 categories in the AJCC 8th edition staging system, stages IIIA and IIIB are comprised of a conglomerate of patients previously staged as either IIB or III, and patients with nodal disease are migrated to stage IV (Fig. 1b) . In the new 8th edition, stages IA, IB, and II (previously IIA) remained the same. For the 8th edition, there was an increase in the total number of patients comprising stage III (n = 9400, 35.9%), with 5120 patients in stage IIIA (975 previously stage IIB, and 4145 previously stage III) and 4280 patients in stage IIIB (754 previously stage IIB, and 3526 previously stage III). The addition of patients with isolated nodal disease (n = 211, previously stage III) to the stage IV category increased the total number of patients with metastatic disease to 2776 (10.6%).
Overall Survival
Median follow-up for the population was 40.8 months. OS for both staging editions are shown in Fig. 2a and b . In both systems, the hazard ratio (HR) for death increases and the 5-year OS decreases as stage increases (Table 2 ). In the 7th edition, a large incremental increase in HR is noted between stages IIB (75.6%) and III (53.3), whereas in the 8th edition, the incremental increases are smaller between each stage (IIIA: 62.4%; IIIB: 50.1%) [ Table 2 ]. The C-index for the 7th edition staging system (0.72) was comparable with the 8th edition (0.74).
Role of T Stage
When stratified by T stage, 5-year OS for T1 and T2 patients, as staged in the 7th edition, was 78.8 and 58.8% (p \ 0.01), respectively. In the 8th edition, 5-year OS improved for T2 patients (62.6%, p \ 0.01), with T3 and T4 patients demonstrating similar 5-year OS of 53.5 and 56.1% (p = 0.52), respectively ( Fig. 2c and d) .
Role of Nodal Disease
In the 8th edition, patients with N1 disease are grouped with patients with distant metastases and are classified as stage IV. Five-year OS for patients with nodal disease without distant metastases was significantly longer than patients with distant metastases (33.1% vs. 12.4%, p \ 0.001) [ Table 2 and Fig. 2e ], but worse than for patients with localized disease (IIIA: 62.4%; IIIB: 50.1%) [p \ 0.01].
Univariate and Multivariate Analyses
Stratified analyses were performed to assess the impact of T and N stage on survival (Table 3) when controlling for known prognostic factors. As patients with metastatic disease at diagnosis are generally treated with systemic therapy rather than surgical resection, separate multivariate analyses were constructed for patients with localized disease and metastatic disease. On multivariate analysis among patients with localized disease (M0; n = 23,579), older age, race, positive margin status, lymph node-positive disease (N1), and high grade were associated with poorer OS, whereas radiation therapy was protective (Table 3 ). Although T stage remained an independent predictor of OS, little difference was noted between patients with T3 tumors versus T4 tumors (HR 2.12 vs. 2.19) [ Table 3 ].
For patients with metastatic disease (n = 2565) older age, increasing T stage, nodal disease, and high-grade tumors correlated with decreased OS on multivariate analyses, although the overall impact was less than for those with localized disease. In addition, receipt of chemotherapy or radiation therapy was associated with improved outcomes (electronic supplementary Table 1 ).
DISCUSSION
The current study uses the NCDB to evaluate the prognostic power of the 8th edition of the AJCC staging system for extremity and trunk soft tissue sarcoma. The additional T-stage categories and the resultant restaging of patients with large, intermediate-or high-grade tumors stratifies patients into more distinct categories than the 7th edition. Larger tumor size correlated with OS, although no difference was detected between T3 and T4 tumors. Patients with metastatic nodal disease have a prognosis that is intermediate to those without nodal disease and those with distant metastases, and perhaps should be reclassified into a unique staging category (i.e. IIIC).
It is interesting that in this study using a large, US hospital-based database, the addition of the T3 category adds prognostic power, but there is little to no additional discriminatory power among patients with T3 and T4 tumors, suggesting that tumor size correlates well with OS only up to a finite tumor size. These findings are similar to those reported by Maki et al., 5 in which DSS was equivalent for patients with tumors between 10 and 15 cm and [ 15 cm, although the authors showed inferior local disease-free survival (DFS) for patients with tumors larger than 15 cm, forming the basis for the T-stage groups used in the AJCC 8th edition. The current study was not able to assess for local DFS or DSS as these events are not captured in the NCDB. Our findings, and those of Maki et al., 5 support the current 8th edition staging system that groups The role of nodal status in the staging of soft tissue sarcoma is controversial. Nodal metastases are rare, with an incidence between 0.9 and 16.4% of patients in series specific to soft tissue sarcomas of the trunk and extremity, 9-12 although higher rates are observed among specific histologies. 12, 13 Although rare, nodal disease is a significant adverse prognostic factor for survival, and, in a recent Surveillance, Epidemiology, and End Results (SEER) IIA  IIB  III  IV   IA  IB  II  IIIA  IIIB  IV   IA  IB  II  IIIA  IIIB  IVM+  IVN+M-T2   T1   T1  T2  T3 HR hazard ratio, CI confidence interval, OS overall survival, AJCC American Joint Committee on Cancer, N ? node positive, M ? distant metastases analysis, was the strongest prognostic factor for OS after excluding distant metastases (HR 5.1, 95% CI 3.5-7.6, p \ 0.001). 10 In the 6th edition of the AJCC staging system, patients with nodal disease were classified as stage IV, as in the current 8th edition. Because of several studies suggesting that patients with isolated nodal metastases fare better than patients with distant metastatic disease, 7, 14, 15 the 7th edition AJCC staging system downstaged patients with nodal disease to stage III, in the absence of distant metastases; however, these patients had survival outcomes inferior to those patients with large, high-grade tumors without nodal metastases (also included in stage III). 5, 10 In our study, metastatic nodal disease was the strongest prognostic factor for decreased OS in the absence of distant metastases. Patients with nodal disease without distant metastases had survival intermediate to that of the current stage IIIB and IV patients, adding support to the concept that patients with isolated nodal metastases comprise a unique group. Consideration should be given to creating a separate classification (i.e. IIIC or M1a) that denotes these patients' distinct outcomes.
The identification of reliable and consistent prognostic factors for patients with soft tissue sarcoma of the trunk and extremities has been hindered by both the rarity of the disease and the retrospective nature of available reports within the literature. In addition to tumor size and tumor grade, 5, 6, 16, 17 large retrospective series have reported age (either as a continuous variable 5, 6 or age [ 50 years), 16, 17 microscopically positive margins, 6,17 specific histologic subtypes, 6, 17 anatomic site, 5, 16, 17 nodal disease, 5 and recurrence at the time of presentation 6, 17 as adverse prognostic factors for local recurrence, distant recurrence, and DSS. The Memorial Sloan Kettering Cancer Center sarcoma-specific nomogram predicts the risk of sarcomaspecific death within 12 years of curative intent surgical treatment using age, tumor size, depth, tumor site, histology, and grade (low/high), 18, 19 with others adapting the model to a three-grade system. 20 Although we were unable to examine specific histologic subtypes, our data similarly support the role of tumor size, nodal disease, grade, age, and margin status as prognostic factors for survival. Predicting survival is likely to be most accurate when based on a large number of homogeneous patients, including those with similar histologies. Histologic subtype is an accepted prognostic factor for survival, 21 but, with more than 50 subtypes of sarcoma, accounting for each in a single staging system is not practical. In addition to staging systems, nomograms offer a valuable method of conveying patient-specific prognostic information, and their continued refinement and use is encouraged.
The current study has several limitations, many of which stem from the use of a large registry that draws information from multiple providers and coding personnel across multiple institutions. One advantage of the NCDB is that the Committee on Cancer requires multiple quality reviews and direct assessment of the data at each institution to maintain accreditation. Variability within the data remains, as evidenced by the small proportion of cases in the current study with conflicting grade and histology. With more than 50 different histologic subtypes, soft tissue sarcomas comprise a diverse group of pathologies at high risk for diagnostic error. 22 Sarcoma in particular represents a field that has used multiple different grading schema, and specific diagnostic terms have gained or lost popularity over time (e.g. malignant fibrous histiocytoma was declassified as a diagnostic term in 2002 by the World Health Organization, and was replaced by undifferentiated pleomorphic sarcoma), 21 in addition to having multiple categories of 'not otherwise specified'. Additionally, there is inherent ambiguity related to the use of multiple grading systems and the NCDB cannot distinguish which one was used. Although a limitation, the current work does not prognosticate based on individual histologies, and therefore the histologic ambiguity innate to any large database may be less significant with regard to the current findings.
CONCLUSIONS
The current study examines the prognostic power of the new 8th edition AJCC staging system for trunk and extremity soft tissue sarcomas, and shows that the additional T stages ([ 10 cm) identify discrete groups with respect to prognosis, particularly for those patients with intermediate-to high-grade tumors. The distinction between T3 and T4 tumors may not be clinically relevant, and future studies should examine the prognostic factors specific to this population. The inclusion of patients with metastatic nodal disease in the metastatic/stage IV category requires continued evaluation as these patients have an OS that is substantially better than their counterparts with distant metastases.
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